<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Cytokinetics-Incorporated-US23282W6057">Cytokinetics, Incorporated</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/cytokinetics-wins-uk-approval-nice-backing-heart-disease-drug-2026-07-30/">Cytokinetics erhält UK-Zulassung und NICE-Empfehlung für Herzmedikament</a>
    </div>

      <div class="me-0 me-md-5">
        Die britische Arzneimittelbehörde genehmigte am Donnerstag Cytokinetics&#39; Medikament für eine seltene Herzerkrankung, und die britische Kosten-Nutzen-Instanz NICE empfiehlt die Erstattung durch den NHS, wodurch potenziell etwa 6.600 Patienten erreicht werden könnten.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Cytokinetics-Incorporated-US23282W6057">Cytokinetics, Incorporated</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/07/30/3335860/35409/en/Cytokinetics-Announces-MHRA-Marketing-Authorisation-for-MYQORZO-aficamten-and-Positive-Guidance-from-NICE-for-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-in-England-and-Wal.html">Cytokinetics meldet MHRA-Zulassung für MYQORZO®▼ (aficamten) und positive Empfehlung von NICE für symptomatische obstruktive hypertrophe Kardiomyopathie in England und Wales</a>
    </div>

      <div class="me-0 me-md-5">
        Zulassung durch die MHRA und Empfehlung von NICE Diese Mitteilung richtet sich ausschließlich an Wirtschafts‑ und Finanzmedien sowie Investoren  SOUTH SAN FRANCISCO, Calif., 30. Juli 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) gab heute bekannt, dass die Medicines and Healthcare products Regulatory Agency (MHRA) MYQORZO® (aficamten) eine Marktzulassung im gesamten Vereini...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Cytokinetics-Incorporated-US23282W6057">Cytokinetics, Incorporated</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/07/17/3329267/35409/en/Cytokinetics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html">Cytokinetics gibt Inducement-Zuteilungen gemäß Nasdaq-Listing-Regel 5635(c)(4) bekannt</a>
    </div>

      <div class="me-0 me-md-5">
        SOUTH SAN FRANCISCO, Calif., 17. Juli 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) gab heute bekannt, dass sie am 15. Juli 2026 Aktienoptionen zum Kauf von insgesamt 21.220 Stammaktien und 14.067 Restricted Stock Units (RSUs), die bei Vesting in Stammaktien abgerechnet werden, an 10 Mitarbeiter gewährte, deren Beschäftigung im Juni und Juli 2026 begann, als wesentliche Anr...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Cytokinetics-Incorporated-US23282W6057">Cytokinetics, Incorporated</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/07/07/3323061/35409/en/Cytokinetics-Announces-Three-Late-Breaking-Science-Abstracts-at-the-European-Society-of-Cardiology-ESC-Congress-2026.html">Cytokinetics kündigt drei Late-Breaking-Science-Abstracts beim ESC-Kongress 2026 an</a>
    </div>

      <div class="me-0 me-md-5">
        Hot-Line-Präsentation der Primärergebnisse von ACACIA-HCM zur Erläuterung positiver Topline-Ergebnisse bei Patienten mit nicht-obstruktiver hypertropher Kardiomyopathie
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Cytokinetics-Incorporated-US23282W6057">Cytokinetics, Incorporated</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Investors Business Daily</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.investors.com/stock-lists/new-highs/sphere-stock-sphr/">Entertainment Stocks Madison Square Garden, Sphere Rally To New Highs</a>
    </div>

      <div class="me-0 me-md-5">
        Entertainment leader Sphere stock continues to outperform in the current market environment, setting new highs.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Cytokinetics-Incorporated-US23282W6057">Cytokinetics, Incorporated</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/17/3313794/35409/en/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html">Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</a>
    </div>

      <div class="me-0 me-md-5">
        SOUTH SAN FRANCISCO, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2026 it granted stock options to purchase an aggregate of 24,784 shares of common stock and 16,429 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 2,242 performance stock units (PSUs) that, if earned, will be sett...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Cytokinetics-Incorporated-US23282W6057">Cytokinetics, Incorporated</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/08/3307987/35409/en/Cytokinetics-Announces-Call-for-Proposals-for-Annual-Corporate-Giving-Program.html">Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program</a>
    </div>

      <div class="me-0 me-md-5">
        Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is August 3, 2026 SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for its annual Cytokinetics Corporate Giving Program.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Cytokinetics-Incorporated-US23282W6057">Cytokinetics, Incorporated</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/01/3304238/35409/en/Cytokinetics-Launches-MYQORZO-aficamten-in-European-Union-with-First-Commercial-Availability-in-Germany.html">Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany</a>
    </div>

      <div class="me-0 me-md-5">
        European Launch Follows Strong U.S. Start SOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the first commercial European launch of MYQORZO® (aficamten) in Germany for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult pa...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Cytokinetics-Incorporated-US23282W6057/load_more?page=4">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>